Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited
(“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company
developing innovative small molecule and biological therapeutics, today
announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody
GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced
hepatocellular carcinoma (HCC) were published online by the well-known journal
BMC Medicine (Impact factor: 11.806). The results showed that this combination
regimen is well-tolerated and has promising anti-tumor activity in patients
with recurrent advanced HCC, with a confirmed overall response rate (ORR) of
30% and a remarkable long-tail effect.https://doi.org/10.1186/s12916-023-03098-wHCC is a common pathological type of liver
cancer. The early clinical symptoms are not obvious, and 50% of patients are
already in the advanced stage when diagnosed. Systemic therapy is recommended
for advanced HCC. In recent years, the treatment of ad
………………………………
